Table 3.
Permeability of pulmonary epithelium to mannitol and pulmonary absorption of AMPs in the IPRL modela
| Treatment | AMP deposited dose (nmol) | Extent of AMP absorptionb | Mannitol absorption t1/2 (min)c |
|---|---|---|---|
| Control | 18.9 ± 8.4 | ||
| CaLL | 30 ± 0.7 | <3 | 2.6 ± 1.3† |
| CaLL | 3 ± 0.4 | 18.3 ± 1.1 | |
| PEG2-CaLL | 33 ± 5.1 | <3 | 16.1 ± 5.9 |
| LL-37 | 12 ± 0.2 | 0.5 ± 0.1 | 17.8 ± 1.0 |
| Cecropin A | 21 ± 0.2 | <3 | 31.6 ± 1.2† |
a
Data shown are mean ± standard deviation (SD) (n ≥ 3).
b
Extent of AMP absorption was determined at 90 min from the IPRL perfusate concentration and the lung-deposited dose.
c
Mannitol absorption t1/2 was determined by nonlinear regression of the cumulative transport curves. †, P < 0.05 compared to control by one-way analysis of variance (ANOVA) and Dunnett's post hoc test.